Fevipiprant

N/A

Report date: 2025/06/10 20:00:09
NME

Base Information

Drug NameFevipiprant
Drug Alias Name菲维匹仑Fevipiprantum非维匹仑QAW-039NVP-QAW-039
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin D2 receptor antagonistsProstaglandin D2 receptor 2 antagonists
TargetsProstaglandin D2 receptorProstaglandin D2 receptor 2
Therapy Area/IndicationsDermatitis, AtopicEosinophiliaRenal Insufficiency +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgCatalent Germany Schorndorf GmbhChina Novartis Institutes For Biomedical Research Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsDermatitis, AtopicEosinophiliaRenal Insufficiency +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG